A Phase I, Randomized, Placebo-Controlled, Double-Blind, Single Dose, Escalating Dose and Multiple-Dose Study of the Safety and Pharmacokinetics of RA101495 in Healthy Volunteers

Trial Profile

A Phase I, Randomized, Placebo-Controlled, Double-Blind, Single Dose, Escalating Dose and Multiple-Dose Study of the Safety and Pharmacokinetics of RA101495 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs RA 101495 (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; First in man
  • Sponsors Ra Pharmaceuticals
  • Most Recent Events

    • 06 Mar 2017 According to a Ra Pharmaceuticals media release, data from this study presented at the International PNH Interest Group Annual Scientific Assembly on December 2, 2016 in San Diego.
    • 30 Nov 2016 Results will be presented at the International PNH Interest Group Annual Scientific Assembly 2016, according to a Ra Pharmaceuticals media release.
    • 27 Jun 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top